The purpose of the study is to determine whether the new medicine works as well as the existing one. Participants will receive a series of these eye injections over several months and will have regular eye examinations. Vision will be checked using a test called BCVA, measured with an ETDRS chart, which is a standardized eye chart used to assess how well a person can read letters. Doctors will also look for signs of fluid inside the retina, called IRF and SRF, and will measure the size of the abnormal blood‑vessel area, known as CNV, using imaging methods such as FA and SD-OCT. Safety will be monitored throughout the study, including checking for any immune reactions called ADAs.

The purpose of the trial is to determine whether the new drug works at least as well as the existing treatment in preserving or improving vision. Vision will be assessed using a standard test called Best-Corrected Visual Acuity, which measures how many letters a person can read on an eye chart, reported in ETDRS letters.

Participants will receive a series of eye injections over roughly one year, with regular visits to check eye health, vision scores, and any side effects. The study is designed so that neither the participants nor the doctors know which medication is being given at each visit.

The study follows people for a long period and looks at whether normal thyroid function can be kept after treatment has been stopped. During the study, adults receive the study medicine and are then observed over time to see whether thyroid levels remain stable without ATD (anti-thyroid drugs, medicines that lower thyroid hormone). Some participants may stop the study medicine earlier or later than others as part of the study plan. The study also checks whether TRAb (thyroid-stimulating hormone receptor antibodies, proteins made by the immune system that can affect the thyroid) are no longer found in the blood.

The study is designed as a long-term extension, meaning it continues to follow people who have already taken part in earlier research with this medicine. Information is collected over many months, with the main follow-up lasting up to 52 weeks after treatment changes. The study uses groups of participants to compare how long thyroid control lasts after stopping treatment and how often the disease returns, also called a relapse.

During the study, participants will receive either AVT29 or a high dose of Eylea. The medical team will monitor changes in best-corrected visual acuity, which refers to the clearest vision possible with glasses or contact lenses. Additionally, the study will look at changes in central subfield thickness, a measurement of how much the middle part of the retina has thickened due to swelling, and the presence of intraretinal fluid, which is liquid trapped inside the layers of the retina. Regular check-ups will also be performed to monitor intraocular pressure, the fluid pressure inside the eye, and other general health factors to ensure safety throughout the process.

People taking part in the study will be randomly assigned to receive either one injection of the experimental treatment or regular injections of the approved medication. Before starting the main part of the study, participants will receive one injection of the approved medication to make sure their condition responds to this type of treatment. During the study, doctors will measure vision using an eye chart and will take images of the eye to see how the condition is changing. The main measurement will be the change in vision after one year of treatment. Doctors will also track how many additional injections are needed and whether the experimental treatment can reduce the need for repeated injections compared to the standard treatment.

The study will last several years and will continue to follow participants to see how long the effects of the treatments last. Throughout the study, participants will have regular visits where their vision will be tested and their eyes will be examined. The study aims to determine whether the single injection of gene therapy can provide lasting benefits and reduce the treatment burden for people with this eye condition.

The purpose of this research is to determine how well IMVT-1402 works compared to placebo in treating adults with Graves’ Disease. The study examines the medication’s effects on thyroid hormone levels and the need for standard thyroid medications over a 26-week period.

During the study, participants will receive either IMVT-1402 injections or placebo. The medication will be given as a subcutaneous injection, which means it is administered under the skin. The maximum daily dose of the study medication can be up to 600 milligrams. The study will monitor how the treatment affects thyroid hormone levels and overall thyroid function throughout the treatment period.

The purpose is to determine if using both medications together works better than empagliflozin alone in preventing serious heart-related health issues in people with these three conditions. The study will particularly look at how well this combination prevents death from heart problems and reduces the need for hospital visits due to heart failure.

Participants in this study will receive treatment for about 51 months. During this time, they will take either the combination of both medicines or empagliflozin with a placebo. Their blood pressure, kidney function, and heart health will be monitored throughout the study period. The medications being tested are designed to help manage blood sugar levels and blood pressure while protecting the heart and blood vessels.

The purpose of the study is to evaluate how effective and safe TOUR006 is in treating people with Thyroid Eye Disease. Participants in the study will receive either the new treatment or a placebo, which is a substance with no active medication. The study will last for several weeks, and participants will receive regular injections and attend follow-up visits to monitor their progress. The main goal is to see if the treatment can reduce the eye bulging by at least 2 millimeters without worsening the condition in the other eye.

Throughout the study, participants will be monitored for any changes in their condition, including improvements in eye bulging and other symptoms like double vision. The study will also track any side effects or adverse events that may occur. The results will help determine if TOUR006 is a viable treatment option for people with Thyroid Eye Disease.

Participants are randomly assigned to receive either BP05 or Lucentis, and both the participants and the doctors will not know which treatment is given to maintain objectivity in the results. This type of study is known as “double-blind.” Some participants may also receive a placebo, a treatment with no active medication, to further assess the effectiveness of these drugs.

The study aims to assess how well these treatments can improve vision by measuring changes in visual acuity, which determines the clarity of vision, and other factors such as the size of areas affected by the disease in the eye. The study will involve several visits and tests over time to track improvements or side effects, helping to gather comprehensive data on the impacts of these treatments.

Participants in the study will be those who have been recently hospitalized with heart failure and have a certain level of heart function, measured by something called the ejection fraction. This is a percentage that shows how well the heart is pumping blood. The study will involve taking the medication or placebo for a period of time, and researchers will monitor the participants for any heart-related events or changes in their condition.

The study aims to gather information on the effectiveness and safety of finerenone in managing heart failure symptoms and improving survival rates. By comparing the outcomes of those taking finerenone with those taking a placebo, researchers hope to better understand the potential benefits of this treatment for patients with heart failure.

Participants in the study will receive Batoclimab through a subcutaneous injection, which means it is injected under the skin. The treatment will be administered once a week for a total of 24 weeks. For the first 12 weeks, participants will receive a dose of 680 mg, followed by a reduced dose of 340 mg for the remaining 12 weeks. Some participants will receive a placebo, which looks like the treatment but does not contain the active substance.

The study aims to observe changes in the condition of the eyes, specifically looking at the reduction in eye protrusion, known as proptosis, by the end of the 24-week period. The trial will also monitor other aspects of the disease, such as changes in eye inflammation and overall eye health. The goal is to determine if Batoclimab can effectively improve symptoms of TED compared to the placebo.

Participants in this study have previously completed another study involving Batoclimab. This extension study allows researchers to continue monitoring the effects of the treatment over a longer period. The study involves regular injections of Batoclimab and periodic assessments to track the progress of the treatment. Participants will not undergo any immediate surgical interventions or other medical therapies for TED during the study period.

The study aims to understand how long the positive effects of Batoclimab last after stopping the treatment and to evaluate the proportion of participants who respond to the treatment. This information will help determine the long-term benefits and safety of Batoclimab for individuals with Thyroid Eye Disease.

The purpose of this study is to ensure that the AVT06 pre-filled syringe is handled correctly and safely, and to evaluate the safety of the treatment when injected into the eye. Participants in the study will receive the treatment through an injection into the eye, known as intravitreal use. The study will follow participants over a period to monitor the safety and effectiveness of the treatment. There is also an optional extension phase for further observation.

Throughout the study, the focus will be on the successful administration of the treatment and monitoring any side effects related to the eye. The study aims to provide valuable information on the safe use of Aflibercept in treating these eye conditions, helping to improve treatment options for patients with these diseases.

Participants in the study will be randomly assigned to receive either asundexian or apixaban. Some participants will receive a placebo, which is a substance with no active medication, to help compare the effects of the treatments. The study will be conducted in a double-blind manner, meaning neither the participants nor the researchers will know who is receiving which treatment, to ensure unbiased results. The trial will last for a period of up to 33 days, during which the safety and effectiveness of the treatments will be closely monitored.

The main goal is to see if asundexian is at least as effective as apixaban in preventing stroke and systemic embolism, and to assess the risk of major bleeding, which is a significant concern with blood-thinning medications. The study will also look at other outcomes, such as the occurrence of minor bleeding, cardiovascular events, and overall mortality. This research aims to provide valuable information on the potential benefits and risks of asundexian compared to apixaban for people with atrial fibrillation at risk of stroke.